Structure via PubChem · Public domain (PubChem)
bortezomib
Sign in to saveAlso known as peptide boronate, [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, N-[(1R)-1-(dihydroxyboryl)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications. It is given by injection.
Chemical data
- Formula
- C19H25BN4O4
- Molecular weight
- 384.2 g/mol
- IUPAC name
- [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
- SMILES
- B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
- InChIKey
- GXJABQQUPOEUTA-RDJZCZTQSA-N
- Polar surface area
- 124 Ų
- H-bond donors
- 4
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
12,659 papers- Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors.Life sciences · 2024
- Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.Targeted oncology · 2023
- Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.Current treatment options in oncology · 2024
- Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.Blood cancer journal · 2020
- Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.Journal of microencapsulation · 2021
via PubMed
Wikidata facts
- Mass
- 384.197
- Manufacturer
- Pfizer
- Has use
- medication
Show 8 more facts
- chemical formula
- C₁₉H₂₅BN₄O₄
- medical condition treated
- diffuse large B-cell lymphoma
- isomeric SMILES
- B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
- canonical SMILES
- B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
- World Health Organisation international non-proprietary name
- bortezomib
- Commons category
- Bortezomib
- subject has role
- antineoplastic
- significant drug interaction
- phenytoin
Sources (6)
via Wikidata · CC0
~9 min read
Encyclopedic overview
12 sectionsContents
- Medical use
- Adverse effects
- Drug interactions
- Pharmacology
- Structure
- Mechanism
- Pharmacokinetics and pharmacodynamics
- History
- Society and culture
- Economics
- References
- External links
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications. It is given by injection.
Common side effects include nausea, diarrhea, tiredness, low platelets, fever, numbness, low white blood cells, shortness of breath, rash and abdominal pain. Other severe side effects include low blood pressure, tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome. It is in the class of medications known as proteasome inhibitor. It works by inhibiting proteasomes, cellular complexes that break down proteins.
Excerpted from Wikipedia’s “bortezomib” article, available under the CC BY-SA 4.0 licence.